AI Article Synopsis
- Quinoline-based fibroblast activation protein inhibitors (FAPIs) are gaining attention in nuclear medicine for their potential in both cancer treatment and diagnosing non-cancer diseases.
- The review explores the progress of FAPI tracers in China, detailing their transition from preliminary research to clinical applications while highlighting their effectiveness in detecting common cancers.
- Additionally, the review evaluates the role of FAPI PET in managing cancers and other medical conditions, aiming to inform future research directions in this area.
Article Abstract
Quinoline-based fibroblast activation protein (FAP) inhibitors (FAPIs) have recently emerged as a focal point in global nuclear medicine, underscored by their promising applications in cancer theranostics and the diagnosis of various nononcological conditions. This review offers an in-depth summary of the existing literature on the evolution and use of FAPI tracers in China, tracing their journey from preclinical to clinical research. Moreover, this review also assesses the diagnostic accuracy of FAPI PET for the most common cancers in China, analyzes its impact on oncologic management paradigms, and investigates the potential of FAP-targeted radionuclide therapy in patients with advanced or metastatic cancer. This review also summarizes studies using FAPI PET for nononcologic disorders in China. Thus, this qualitative overview presents a snapshot of China's engagement with FAPI tracers, aiming to guide future research endeavors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2967/jnumed.123.266983 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!